Plasma eicosanoid profiling in the course of proprotein convertase Subtilisin-Kexin type 9 inhibition: Insights from a metabolomic analysis

被引：0
|
作者：
Schrutka, L. [1 ]
Hagn, G. [2 ]
Galli, L. [1 ]
Poeschl, A. [1 ]
Seidl, V [1 ]
Ondracek, A. S. [1 ]
Bileck, A. [2 ]
Lang, I [1 ]
Hengstenberg, C. [1 ]
Krychtiuk, K. [1 ]
Speidl, W. [1 ]
Gerner, C. [2 ]
Distelmaier, K. [1 ]
机构：
[1] Med Univ Wien, Vienna, Austria
[2] Univ Wien, Vienna, Austria
来源：
WIENER KLINISCHE WOCHENSCHRIFT | 2022年 / 134卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
11-8
引用
收藏
页码：160 / 161
页数：2
相关论文
共 50 条
  • [41] Proprotein convertase subtilisin/kexin type 9: from genetics to clinical trials
    Stoekenbroek, Robert M.
    Kastelein, John J. P.
    CURRENT OPINION IN CARDIOLOGY, 2018, 33 (03) : 269 - 275
  • [42] Effect of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors on Plasma Ceramide Levels
    Ye, Qian
    Svatikova, Anna
    Meeusen, Jeffrey W.
    Kludtke, Erica L.
    Kopecky, Stephen L.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 128 : 163 - 167
  • [43] Proprotein convertase subtilisin/kexin type 9 inhibition: A novel approach for the treatment of hypercholesterolemia?
    Comas, Daniel
    Lopez-Perez, Elvira
    Pilot, Julia
    Martres, Paul
    Fouchet, Marie-Helene
    Duff, Chris
    Scott, Martin
    Courtney, Mary
    Clark, Steve
    Diez, Emilio
    Dominguez, JuanManuel
    Dowell, Simon
    Ancellin, Nicolas
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2008, 28 (06) : E128 - E128
  • [44] Proprotein convertase subtilisin-kexin type 9 as a biomarker for the development and severity of coronary artery disease in general population
    Li, S.
    Xu, R. -X.
    Zhang, Y.
    Guo, Y. -L.
    Zhu, C. -G.
    Wu, N. -X.
    Qing, P.
    Liu, G.
    Dong, Q.
    Li, J. J.
    EUROPEAN HEART JOURNAL, 2015, 36 : 930 - 930
  • [45] Adiposity Blunts the Positive Relationship of Thyrotropin with Proprotein Convertase Subtilisin-Kexin Type 9 Levels in Euthyroid Subjects
    Kwakernaak, Arjan J.
    Lambert, Gilles
    Kobold, Anneke C. Muller
    Dullaart, Robin P. F.
    THYROID, 2013, 23 (02) : 166 - 172
  • [46] Statins, Plasma Proprotein Convertase Subtilisin/Kexin Type 9 Concentrations, and LDL Lowering
    Khera, Amit
    CLINICAL CHEMISTRY, 2012, 58 (01) : 6 - 7
  • [47] An Exploratory Analysis of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial
    Bergmark, Brian A.
    O'Donoghue, Michelle L.
    Murphy, Sabina A.
    Kuder, Julia F.
    Ezhov, Marat V.
    Ceska, Richard
    Gouni-Berthold, Ioanna
    Jensen, Henrik K.
    Tokgozoglu, S. Lale
    Mach, Francois
    Huber, Kurt
    Gaciong, Zbigniew
    Lewis, Basil S.
    Schiele, Francois
    Jukema, J. Wouter
    Pedersen, Terje R.
    Giugliano, Robert P.
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2020, 5 (06) : 709 - 713
  • [48] Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: Relationship with lipoprotein response to antiproteinuric treatment
    Kwakernaak, Arjan J.
    Lambert, Gilles
    Slagman, Maartje C. J.
    Waanders, Femke
    Laverman, Gozewijn D.
    Petrides, Francine
    Dikkeschei, Bert D.
    Navis, Gerjan
    Dullaart, Robin P. F.
    ATHEROSCLEROSIS, 2013, 226 (02) : 459 - 465
  • [49] Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9
    Miao, Ji
    Manthena, Praveen V.
    Haas, Mary E.
    Ling, Alisha V.
    Shin, Dong-Ju
    Graham, Mark J.
    Crooke, Rosanne M.
    Liu, Jingwen
    Biddinger, Sudha B.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2015, 35 (07) : 1589 - 1596
  • [50] Proprotein convertase subtilisin/kexin type 9 (PCSK9) and inhibitors
    Avci, Ahmet
    Demir, Kenan
    Altunkeser, Bulent Behlul
    TURK KARDIYOLOJI DERNEGI ARSIVI-ARCHIVES OF THE TURKISH SOCIETY OF CARDIOLOGY, 2014, 42 : 56 - 67
12345